Payment overview · 2025
General Payments
$345.49
22 reported records · 9 companies
Healthcare provider profile · identity verified
Angela A Powell, MD
Allopathic & Osteopathic Physicians|Family Medicine · MONROEVILLE, AL · NPI 1265478663
Verified facts
What the public records show
CMS Open Payments records show Angela A Powell, MD received $345.49 in general payments during 2025 across 22 reported records.
ABBVIE INC. accounted for 43.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $150.76 | 43.6% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $54.78 | 15.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.18 | 9.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.21 | 6.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.00 | 6.1% | 4 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.96 | 5.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.28 | 4.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.97 | 4.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.35 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $345.49 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $150.76 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $76.99 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.18 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.00 | 4 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 64 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 80 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 18 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 328 | 95 |
| Atorvastatin Calcium | Atorvastatin Calcium | 283 | 81 |
| Gabapentin | Gabapentin | 248 | 70 |
| Potassium Chloride | Potassium Chloride | 203 | 51 |
| Furosemide | Furosemide | 179 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 178 | 42 |
| Omeprazole | Omeprazole | 178 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 177 | 47 |
| Tramadol Hcl | Tramadol Hcl | 177 | 63 |
| Famotidine | Famotidine | 166 | 34 |
| Donepezil Hcl | Donepezil Hcl | 154 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 42 |
| Lisinopril | Lisinopril | 136 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 118 | 38 |
| Metformin Hcl | Metformin Hcl | 113 | 32 |
| Pregabalin | Pregabalin | 113 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 111 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 108 | 26 |
| Trazodone Hcl | Trazodone Hcl | 107 | 25 |
| Alendronate Sodium | Alendronate Sodium | 103 | 28 |
| Carvedilol | Carvedilol | 95 | 22 |
| Losartan Potassium | Losartan Potassium | 88 | 24 |
| Eliquis | Apixaban | 87 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 24 |
| Clonazepam | Clonazepam | 80 | 12 |
| Ozempic | Semaglutide | 80 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 16 |
| Meloxicam | Meloxicam | 75 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 72 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 18 |
| Clonidine Hcl | Clonidine Hcl | 69 | 22 |
| Buspirone Hcl | Buspirone Hcl | 65 | 12 |
| Mounjaro | Tirzepatide | 64 | 14 |
| Lorazepam | Lorazepam | 62 | 20 |
| Memantine Hcl | Memantine Hcl | 62 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 24 |
| Montelukast Sodium | Montelukast Sodium | 60 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 15 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 57 | 11 |
| Divalproex Sodium | Divalproex Sodium | 56 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 16 |
| Azithromycin | Azithromycin | 53 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 17 |
| Sertraline Hcl | Sertraline Hcl | 51 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 12 |
| Levetiracetam | Levetiracetam | 47 | suppressed |
| Simvastatin | Simvastatin | 47 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 39 |
| Tradjenta | Linagliptin | 46 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 11 |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 13 |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 42 | 18 |
| Ezetimibe | Ezetimibe | 41 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | suppressed |
| Mirtazapine | Mirtazapine | 38 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Linzess | Linaclotide | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Risperidone | Risperidone | 33 | suppressed |
| Metolazone | Metolazone | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 32 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 28 | suppressed |
| Prednisone | Prednisone | 27 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Fluconazole | Fluconazole | 25 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Humalog | Insulin Lispro | 23 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 15 | 15 |
| Clonidine | Clonidine | 15 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 13 |
| Spironolactone | Spironolactone | 15 | suppressed |
| Symproic | Naldemedine Tosylate | 15 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Osphena | Ospemifene | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 13 |
| Diazepam | Diazepam | 13 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Glucagon Emergency Kit | Glucagon | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $345.49 · 22 records | ABBVIE INC. | CAPLYTA, Jornay PM, MOUNJARO, Ozempic, REPATHA, REXULTI, Rybelsus, VOQUEZNA, VRAYLAR, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error